Jonathan Alspaugh - Jul 6, 2021 Form 4 Insider Report for Aeglea BioTherapeutics, Inc. (AGLE)

Role
Chief Financial Officer
Signature
/s/ Steven Weber, by power of attorney
Stock symbol
AGLE
Transactions as of
Jul 6, 2021
Transactions value $
$0
Form type
4
Date filed
7/8/2021, 05:12 PM
Next filing
Aug 18, 2021

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AGLE Employee Stock Option (right to buy) Award $0 +160K $0.00 160K Jul 6, 2021 Common Stock 160K $7.03 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The options will vest as to 1/4th of the total shares on July 6, 2022, and then 1/48th of the shares will vest monthly thereafter, such that the option is fully vested on July 6, 2025, subject to the Reporting Person's provision of service to the Issuer on each vesting date.